Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more
Pila Pharma AB (PILA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.644x
Based on the latest financial reports, Pila Pharma AB (PILA) has a cash flow conversion efficiency ratio of -1.644x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.91 Million) by net assets (Skr1.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pila Pharma AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pila Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pila Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pila Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digistar Corporation Bhd
KLSE:0029
|
0.010x |
|
CopperEx Resources Corporation
V:CUEX
|
-0.006x |
|
Amfin Financial Corp
PINK:AFNL
|
N/A |
|
Highway 50 Gold Corp
PINK:HGGCF
|
-0.025x |
|
DONTNOD Entertainment SA
PA:ALDNE
|
-0.071x |
|
Interpace Biosciences Inc
OTCQX:IDXG
|
-6.503x |
|
Tactical Resources Corp.
PINK:USREF
|
0.002x |
|
MBB (MBB.SG)
STU:MBB
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Pila Pharma AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pila Pharma AB from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr14.78 Million | Skr-9.19 Million | -0.621x | +58.21% |
| 2024-12-31 | Skr5.26 Million | Skr-7.82 Million | -1.487x | -104.07% |
| 2023-12-31 | Skr6.66 Million | Skr-4.85 Million | -0.729x | +23.61% |
| 2022-12-31 | Skr9.53 Million | Skr-9.09 Million | -0.954x | -208.63% |
| 2021-12-31 | Skr30.30 Million | Skr-9.36 Million | -0.309x | +47.16% |
| 2020-12-31 | Skr3.42 Million | Skr-2.00 Million | -0.585x | +13.15% |
| 2019-12-31 | Skr7.46 Million | Skr-5.02 Million | -0.674x | +4.17% |
| 2018-12-31 | Skr6.49 Million | Skr-4.56 Million | -0.703x | -- |